COYA — Coya Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1835022 ·
Last close
$4.19
Market Cap
$98.29M
52W High
$6.21
52W Low
$3.86
ADV30
250,690
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 251,147 | — | -7,640,217 | -7,206,990 | 53,271,099 | 50,724,643 | 4,300,739 |
| Dec 2025 | 3,959,999 | — | -6,030,888 | -5,708,542 | 49,950,245 | 46,822,786 | 6,922,015 |
| Sep 2025 | 3,564,254 | — | -2,432,897 | -2,115,831 | 32,042,878 | 28,129,866 | 4,758,387 |
| Jun 2025 | 163,616 | — | -6,414,518 | -6,094,977 | 33,452,555 | 29,757,328 | 5,142,262 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,119,556
Investing CF
$-2,049,602
Financing CF
$31,363,177
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-69,170,267
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-22,518,520
Pretax Income TTM
$-21,123,251
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,939,016
EBITDA
$-20,195,590
Free Cash Flow
$-9,747,224
Enterprise Value
$47,560,952
Total Cash
$50,724,644
Total Debt
$0
Shares Out
23,457,183
Trailing EPS
$-1.15
Book Value
$2.09
ROE
-51.3%
ROA
-27.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,945,753 | -22,555,225 | -21,226,107 | 49,950,245 | 6,922,015 | — | -10,739,301 |
| Dec 2024 | 3,554,061 | -17,249,711 | -14,880,787 | 44,347,016 | 4,769,921 | — | -10,288,822 |
| Dec 2023 | 6,002,206 | -7,903,349 | -7,987,836 | 41,262,274 | 5,626,665 | — | -11,188,811 |
| Dec 2022 | 0 | -9,811,939 | -12,244,776 | 8,395,566 | 16,789,111 | — | -7,239,354 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.83
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $4.19 · call volume: 10 · put volume: 14
Expected Move to 2026-08-21:
±$2.46
(58.71%) —
implied range
$1.73 –
$6.65
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HSTC | HST Global, Inc. | $99.00M | $0.70 | — |
| RFL | Rafael Holdings, Inc. | $99.35M | $1.94 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $100.09M | $6.68 | — |
| RVRC | Revium Rx. | $101.42M | $1.67 | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $94.64M | $0.50 | — |
News headlines (Yahoo Finance, 1h cache)
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
2026-06-30 13:40 · Yahoo
Coya Therapeutics secures FDA fast track status for COYA 302
2026-05-14 11:15 · Yahoo
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs
2026-05-12 12:35 · Yahoo
NanoViricides to Participate at D. Boral Capital Global Conference in NYC
2026-05-07 12:35 · Yahoo
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA
2026-05-06 12:35 · Yahoo
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
2026-02-25 17:00 · Yahoo
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar
2026-02-17 21:35 · Yahoo
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
2026-01-31 13:15 · Yahoo
ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman
2025-12-02 21:46 · Yahoo
RoboMarkets expands trading opportunities with over 1,300 additional US stocks and ETFs
2025-11-20 08:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.